You are here: Home > Projects and Research lines > A phase III randomized, double-blinded, placebo-controlled study of sorafenib as an adjuvant therapy for hepatocellular carcinoma after surgical resection or local ablation (STORM)
Projects and Research lines
A phase III randomized, double-blinded, placebo-controlled study of sorafenib as an adjuvant therapy for hepatocellular carcinoma after surgical resection or local ablation (STORM)

Bayer Pharmaceuticals

Clinical research: Clinical trials in liver cancer

Liver Cancer Translational Research Laboratory

BCLC-IDIBAPS, Liver Unit, Hospital Clínic · Esther Koplowitz Center, 3rd Floor
Rosselló 153 · 08036 Barcelona · Tel: +34 93 227 9155

© Liver Cancer Translational Research Laboratory - IDIBAPS 2011 - 2017